News
Important Only
Trump Reignites War of Words — Declares He Is Considering Deporting Musk!
TradingKey – As the U.S. Senate moves forward with the so-called “Big Beautiful” bill, opposition within the country is growing stronger. Tesla CEO and former head of the Department of Government Efficiency (DOGE), Elon Musk, has once again criticized the legislation.
TradingKey
Wed, Jul 2
Why Dollar General Stock Jumped 18% in June
Shares of Dollar General (NYSE: DG) were among the winners last month as the discount retailer soared on better-than-expected results in its first-quarter earnings report and benefited from an upward trend in the stock market over the rest of the month.In the end, it was enough to push the retail st...The Motley Fool
Wed, Jul 2
Why Block Stock Zoomed 10% Higher in June
Block (NYSE: XYZ) had a decent, if unspectacular, June, ultimately emerging from the month with a 10% gain in share price. A product launch in an important market overseas, announced as we approached July, was a catalyst, as were several positive analyst notes across the preceding weeks.A good month...The Motley Fool
Wed, Jul 2
S.Korean shares drop as US ramps up trade pressure ahead of tariff deadline
KOSPI falls, foreigners net sellersKorean won weakens against dollarSouth Korea benchmark bond yield rises SEOUL, July 2 (Reuters) - Round-up of South Korean financial markets: ** South Korean shares fell on Wednesday as U.S. President Donald Trump stepped up his rhetoric and increased press...Reuters
Wed, Jul 2
Australia's Neurizon Therapeutics jumps on licensing agreement with Elanco
** Shares of Neurizon Therapeutics NUZ.AX rise as much as 3.2% to A$0.160, their biggest intraday pct gain since June 26** The biotechnology co enters into a global licensing agreement with Elanco Animal Health ELAN.N** Agreement is for exclusive rights to Elanco's data package and related intel...Reuters
Wed, Jul 2
24H｜Tesla Rises 1%; Wolfspeed Jumps 5% After Soaring 98% Tuesday; U.S. Health Insurer Shares Fall; Centene Drops 23%; Oscar Health down 6%
Tesla Motors shares rose 1% in overnight trading following 5% drop in the prior session. Wolfspeed Inc. rallied 5% in overnight trading after soaring 98% in the previous trading day.U.S. health insurer shares fell in overnight trading. Centene fell 23%; Molina Healthcare fell 8%; Oscar Health fell 6...Tiger News
Wed, Jul 2
Why Uber Stock Was in the Fast Lane in June
The biggest story in June concerning autonomous driving was Tesla's long-awaited robotaxi launch, but the news surrounding Uber Technologies (NYSE: UBER) could have a bigger impact in the near term.Shares of Uber climbed 10.9% in June, according to data provided by S&P Global Market Intelligence, on...The Motley Fool
Wed, Jul 2
Why Joby Aviation Soared Higher in June
Joby Aviation (NYSE: JOBY) reached a historic milestone in its effort to bring "flying taxis" to the masses, and investors responded by sending the stock to higher altitudes.Joby shares soared 34.9% in June, according to data provided by S&P Global Market Intelligence, after the company's aircraft t...The Motley Fool
Wed, Jul 2
GLOBAL MARKETS-Asian stocks waver, dollar frail as Trump's tariffs, US rate path weighs
Asian stocks ease from multi-year high touched last weekDollar loiters near 3-1/2-year lows; Euro, yen firmsPowell reiterates wait-and-see approach to rate cutsTrump's tax bill passes Senate, House of Representatives up next By Ankur Banerjee SINGAPORE, July 2 (Reuters) - Asian stocks slipped...Reuters
Wed, Jul 2
Why AMD Stock Jumped 28% in June
Shares of Advanced Micro Devices (NASDAQ: AMD) were moving higher again last month as the chip stock made more acquisitions to push its AI strategy and unveiled its future plans and goals at its Advancing AI conference.Additionally, the stock benefited from the broader upward trend in stocks on soli...The Motley Fool
Wed, Jul 2
SeaPRwire News Bots Help Readers Receive the Latest Personalized News
Hong Kong - July 01, 2025 - (SeaPRwire) - SeaPRwire, a leading Public Relations Communication Platform, has launched its innovative News Bots system, a cutting-edge AI-based automated program developed in collaboration with Asia Presswire (https:/asiapresswire.com). This new service is designed to provide real-time news updates and personalized news push notifications to readers, ensuring they receive the most relevant and timely information.The News Bots use advanced artificial intelligence algorithms to analyze user preferences and behavior, delivering tailored news updates that match individual interests. Whether it's breaking news, industry updates, or trending stories, the system ensures that users are always informed with the most relevant content, without the need for manual searches or constant updates."With the introduction of News Bots, we are revolutionizing how news is delivered to readers," said Jane Woo, Product Director at SeaPRwire. "Our system provides a seamless, efficient way for users to stay up-to-date with the latest developments in their areas of interest, all while receiving content tailored specifically to them. This not only enhances user experience but also ensures that the news they receive is timely, accurate, and relevant."By utilizing AI technology, News Bots continuously monitor news sources, social media platforms, and other relevant channels to provide instant updates. The personalized nature of the service ensures that readers are not overwhelmed by irrelevant information. Instead, they receive only the news that matters most to them, which enhances engagement and keeps them informed in real time.The platform is particularly beneficial for businesses, PR professionals, and media organizations looking to stay on top of the latest trends and breaking news. By integrating News Bots into their communication strategies, they can ensure that their content reaches the right audience at the right time, maximizing its impact and relevance.As part of SeaPRwire's ongoing commitment to innovation, the News Bots system will continue to evolve with advancements in AI technology, ensuring even greater accuracy and personalization over time. With this powerful tool, users can stay ahead of the curve, receiving personalized news directly to their devices as soon as it becomes available."News Bots provide a level of personalization that traditional news delivery methods simply cannot match," added Jane Woo. "We believe that this will set a new standard for how news is distributed, making it more relevant, timely, and easily accessible for everyone."SeaPRwire's News Bots are now available to clients across the Asia-Pacific region, providing an innovative solution for delivering personalized news updates and enhancing the overall user experience. This new service highlights SeaPRwire's dedication to providing cutting-edge communication tools that empower brands to engage with their audiences more effectively.About Asia PresswireAsia Presswire (https:/asiapresswire.com) is a press release distribution service that provides tailored solutions for public relations firms, agencies, organizations, and corporations worldwide. They specialize in delivering customized press release distribution, including direct-to-editor email delivery to targeted media editors at newspapers, magazines, and broadcast outlets. Their extensive network spans 172 countries, connecting with over 230,000 media outlets and 3.6 million self-media platforms. Supporting over 46 languages, including English, Chinese, French, German, and Japanese, Asia Presswire ensures effective communication across diverse linguistic regions. Their services are designed to enhance brands' online visibility and reputation, enabling effective connection with target audiences. About SeaPRwireSeaPRwire is a leading earned media communications management platform in Asia, designed to empower PR and communications professionals. Its Branding-Insight Program streamlines communication management by connecting clients with a network of over 80,000 journalists, editors, magazines, and online media outlets, along with 300 million followers of key opinion leaders (KOLs). Leveraging AI-driven technology, SeaPRwire enables users to identify relevant media and KOLs, personalize pitches, and measure the impact of their communications efforts. Operating across regions including Japan, China, Korea, Hong Kong, Singapore, Vietnam, Thailand, Malaysia, Indonesia, and the Philippines, SeaPRwire enhances brand awareness and educates audiences effectively.Media ContactBrand: SeaPRwireContact: Media teamEmail: cs@seaprwire.comWebsite: https://seaprwire.com02/07/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Wed, Jul 2
Johnson Controls Celebrates 140 years of Innovation and Leadership
Over 40 Years of Dedicated Partnership and Growth in Singapore's Transformation Journey SINGAPORE, July 2, 2025 /PRNewswire/ -- Johnson Controls (NYSE: JCI), the global leader for smart, healthy, safe and sustainable buildings, is celebrating 140 years of achievements and industry-first...PR Newswire
Wed, Jul 2
Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha
On June 27, 2025, Uni-Bio Science Group Limited (the “Group”)grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌顏態® and the medical device brand 金因敷®. Many experts, KOLs and partners attended the event. This launch not only showcased the Group's achievements in R&D, but also marked the comprehensive layout in the "drug, medical device and Aesthetics" field. （Photo: : group photo at the launch ）High-end medical aesthetics: GeneQueens seriesAt the launch, the Group unveiled the high-end series of 肌顏態® -——GeneQueensTM (Human-Sequence Triple Protein Repair & Balance Ampoule). which functions on skin repair and anti-aging. By activating cell regeneration, it helps users restore their youthful and healthy skin condition.（Photo: GeneQueens product image）GeneQueensTM sets a new standard for anti-aging and repair by adding three core ingredients in sufficient quantities. Skbrella FN, as a key ingredient for cell repair, can accelerate the healing of skin wounds and promote the adhesion and migration of new cells. III Collagen strongly fills the skin structure, significantly enhancing elasticity and firmness. XVII Collagen can strengthen the connection between the epidermis and dermis, and consolidate the youthful foundation of the skin.In addition, GeneQueens adopts a sterile and preservative-free formula, relying on high-purity raw materials and patented technology, providing users with an "instant enjoyment" precise and efficient experience. Its unique formula and outstanding efficacy were highly recognized by many experts on the spot.2、金因敷 showcased a variety of new productsMeanwhile, the Group also launched several new products of its medical device brand - 金因敷®, focusing on the professional repair field of medical aesthetics.（Photo: 金因敷 series product picture）金因敷® complies with strict clinical trials and quality inspections to ensure its safety and effectiveness. The product adopts a high-purity non-allergenic formula, which can moisturize and accelerate wound repair. It also uses an exclusive cooling technology to relieve postoperative swelling and pain, providing a professional solution for sensitive skin and post-medical procedure care.3、The latest research data was presented at CSD2025It is worth mentioning that 肌顏態® also showcased the research data of "The Efficacy Study of Fibronectin in the Repair of Skin Barrier Damage for the post-medical procedure" jointly conducted with the Cosmetics Testing Center of the Dermatology Hospital of Southern Medical University in the poster area of the 30th Academic Conference of the Chinese Medical Association (CSD2025). This is not only an endorsement of the Group's research capabilities, but also provides experts and scholars in the industry with an opportunity to gain a deeper understanding of the 肌顏態® technology and products.As an annual grand event in the field of dermatology and venereology in China, CSD2025 brings together authoritative experts and scholars in dermatology across the country, presenting multi-dimensional academic achievements and exchanges of ideas. The poster area is one of the core venues of the academic annual conference. Posters are not only an important way for researchers to showcase their scientific research achievements, but also a key link in promotingthe dissemination of academic ideas and the feedback of clinical practice.（Photo: The research poster of 肌顏態 at the CSD 2025）4、Academic speeches by several expertsSeveral clinical experts at the launch further recognized thesignificant clinical valueof 肌顏態® and 金因敷®. The experts highlighted that 肌顏態®’ spatented ingredient, Skbrella FN,demonstrates immense potentialin improving damaged sensitive skin barriers, reducing inflammatory erythema, alleviating discomfort sensationssuch as burning, tightness and itching, as well as enhancing post-laser repair and healing.In the clinical observations over the past few months, many patients treated with 肌顏態® have achieved remarkable therapeutic effects. The symptoms of anesthetic allergy have been rapidly relieved, the inflammatory pigmentation post-laser has significantly improved, the skin barrier has been repaired, and the patient satisfaction rate is extremely high. 金因敷® can effectively reduce redness, swelling and pain for post-medical procedures, accelerate wound healing and shorten the recovery time.(Photo 1: 肌顏態 use case sharing by Professor Shi Ge, Director of the Department of Plastic Surgery of the Sixth Affiliated Hospital of Sun Yat-sen University)(Photo 2: 肌顏態 use case sharing by Professor Ge Lan, from The First Affiliated Hospital of Army Medical University)(Photo 3: Fibronectin clinical trial results sharing by Professor Ye Li, Head of Cosmetics Testing Center at Dermatology Hospital of Southern Medical University)(Photo 4: Mr. Du Wei, CEO of Cosmetics News & Cosmetics Business Online, analyzes cosmetics industry development trends)6、The signing ceremony reflects the market potentialMr. Zhao Zhigang, CEO of Uni-Bio Science Group, emphasized:" We have always adhered to the standards of biopharmaceuticals in creating skin care products. The release of GeneQueens and 金因敷 is an important milestone in building the "Drugs, Medical device and Aesthetics" strategy and creating a full-cycle skin care solution, aiming to meet consumers' increasingly refined skin health needs. "(Photo: Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, addressing the launch event.)Furthermore,Ms. Liu Yihua, President of Global Cosmetics Group, attended the launch as an important guest. Uni-Bio Science Group and Global Cosmetics Group havejointly established a medical research co-creation biological platform. Utilizinggene-editing biosynthesis technology, the platform has launched Skbrella FN – ahighly bioactive recombinant human fibronectinknown as "皮優理".The launch also witnessed a grand strategic signing ceremony. The Group has achieved in-depth cooperation with many well-known medical aesthetics chain institutions and well-known agents. This signing is not only a high recognition of the quality and market potential of GeneQueens and 金因敷®, but also a key step for the Group to accelerate commercialization and expand channels. Through strong alliances with leading channel partners, the Group will reach the core consumers and ensure the rapid release of huge commercial value.(Photo: Group photo of the strategic signing ceremony)The successful holding of this launch not only marks a crucial step for the Group in medical aesthetics and medical devices, but also demonstrates the Group's in-depth layout and forward-looking vision in the "Drugs, Medical device and Aesthetics" strategy. In the future, the Group will continue to be guided by technology and oriented towards clinical value, accelerate product innovation and technological upgrading, constantly enrich pipeline, and meet the growing market demands.About Uni-Bio Science GroupUni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.End02/07/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Wed, Jul 2
Prediction: Buying Tesla Stock Today Could Set You Up for Life
According to most demand projections, electric vehicle (EV) stocks have a bright future. One forecast, for example, believes EV sales should comprise nearly one-third of all new car sales in the U.S. by 2030. That's up from just 3.4% in 2021. Tesla (NASDAQ: TSLA) in particular is in a prime position...The Motley Fool
Wed, Jul 2
Can Nvidia Stock Reach $200 This Year?
Nvidia (NASDAQ: NVDA) stock is back in the market's good graces after plunging earlier this year. Despite reassurances from management, investors were worried about the company's future when China's DeepSeek chatbot came out and further concerned about impact of new tariffs. As Nvidia continues to r...The Motley Fool
Wed, Jul 2
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the future. And it's little wonder why, given analysts project that the obesity drug market could be worth $20...The Motley Fool
Wed, Jul 2
